World Journal of Clinical Cases - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

1735

Figures (1-3)

373

Tables (1-1)

412

Sum=2595

Publishing Process of This Article

Item

Count

Browse

136

Download

631

Sum=767

Mar 16, 2024 (publication date) through Jun 8, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Zhu R, Chen TZ, Sun MT, Zhu CR. Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report. World J Clin Cases 2024; 12(8): 1510-1516 [PMID: 38576806 DOI: 10.12998/wjcc.v12.i8.1510]
URL:	https://www.wjgnet.com/2307-8960/full/v12/i8/1510.htm

Number	Citing Articles
1	Haijuan Yu, Jie Lin, Jian Chen, Lijun Chen, Jianping Zou, Bin Liu, Dan Hu, Youping Xiao, Linhao Yu, Yang Sun. A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1494138
2	Baoyue Pan, He Huang, Ting Wan, Qidan Huang, Shanyang He, Shijie Xu, Siyu Chen, Jiaxin Yin, Jundong Li, Min Zheng. The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1582299